KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Acquisitions & Divestments (2021 - 2023)

Historic Change in Acquisitions & Divestments for Recursion Pharmaceuticals (RXRX) over the last 3 years, with Q3 2023 value amounting to $480000.0.

  • Recursion Pharmaceuticals' Change in Acquisitions & Divestments fell 9922.01% to $480000.0 in Q3 2023 from the same period last year, while for Dec 2024 it was $480000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $480000.0 for FY2023, which is 9979.19% down from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Change in Acquisitions & Divestments stood at $480000.0 for Q3 2023, which was down 9922.01% from $61.5 million recorded in Q3 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Change in Acquisitions & Divestments peaked at $147.6 million during Q1 2022, and registered a low of $480000.0 during Q3 2023.
  • Its 3-year average for Change in Acquisitions & Divestments is $60.1 million, with a median of $61.5 million in 2022.
  • Data for Recursion Pharmaceuticals' Change in Acquisitions & Divestments shows a peak YoY increase of 9922.01% (in 2023) and a maximum YoY decrease of 9922.01% (in 2023) over the last 5 years.
  • Quarter analysis of 3 years shows Recursion Pharmaceuticals' Change in Acquisitions & Divestments stood at $69.2 million in 2021, then fell by 11.05% to $61.5 million in 2022, then plummeted by 99.22% to $480000.0 in 2023.
  • Its Change in Acquisitions & Divestments stands at $480000.0 for Q3 2023, versus $61.5 million for Q3 2022 and $21.4 million for Q2 2022.